Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet
NCT05848986 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2023-05-08
Summary
Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms.
The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases.
The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.
Conditions
- Allergy
Interventions
- OTHER
-
Flow cytometry
Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Principal Investigators
-
CHARLES AMBROISE TACQUARD, MD · University Hospital, Strasbourg, France
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-01
- Primary Completion
- 2023-06-01
- Completion
- 2025-04-01
Countries
- France
Study Locations
More Related Trials
-
The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy
NCT02503800 ·Status: COMPLETED
-
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
NCT00001406 ·Status: RECRUITING
-
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
NCT01573533 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)
NCT00505648 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
NCT03712228 ·Status: COMPLETED ·Phase: PHASE2
-
Monitoring Chronic Urticaria Basophil Irritability by Cytometry
NCT02671006 ·Status: COMPLETED
-
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
NCT03494881 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
NCT00267501 ·Status: RECRUITING
-
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
NCT00640497 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis
NCT07035561 ·Status: COMPLETED ·Phase: PHASE2
-
EoE Food Test Pilot Study
NCT07023380 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Tocilizumab in Patients With Schnitzler's Syndrome
NCT03046381 ·Status: COMPLETED ·Phase: PHASE2
-
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
NCT02007239 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
NCT07067099 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.
NCT03443362 ·Status: UNKNOWN
-
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
NCT00275613 ·Status: COMPLETED ·Phase: PHASE1
-
The Metabolomics of Anaphylaxis to Immunotherapy
NCT01666288 ·Status: WITHDRAWN
-
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00635089 ·Status: COMPLETED ·Phase: PHASE3
-
Severe Bullous Drug Eruption and Filgrastim
NCT04651439 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
International Rare Histiocytic Disorders Registry (IRHDR)
NCT02285582 ·Status: RECRUITING
-
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
NCT06339177 ·Status: RECRUITING
-
Urticaria Facticia Treatment With Omalizumab (UFO)
NCT02169115 ·Status: COMPLETED ·Phase: PHASE2
-
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00262288 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Mast Cell Precursors
NCT00001756 ·Status: COMPLETED
-
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
NCT01359384 ·Status: UNKNOWN